Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Exact Sciences ( (EXAS) ).
On November 19, 2025, Exact Sciences Corporation agreed to be acquired by Abbott Laboratories through a merger in which Exact will become an indirect, wholly owned subsidiary of Abbott. To address potential tax implications under Sections 280G and 4999 of the U.S. Internal Revenue Code tied to this transaction, Exact’s Human Capital Committee, advised by a Section 280G consultant, approved Acceleration and Clawback Agreements for its active named executive officers on December 23, 2025, accelerating payment of their fiscal 2025 bonuses at 115% of target and the vesting of certain restricted stock units and performance share units at above-target performance levels. The arrangements specify precise bonus amounts and share accelerations for each executive and include clawback provisions requiring repayment if employment terminates under conditions that would have led to forfeiture, as well as potential true-up payments if actual 2025 performance ultimately exceeds the assumed performance levels, aligning executive compensation mechanics with the pending merger structure while managing excise tax exposure for the company and its leadership.
The most recent analyst rating on (EXAS) stock is a Buy with a $111.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Outperform.
Exact Sciences’ stock is bolstered by strong technical momentum and a positive corporate event with the merger announcement. However, profitability challenges and valuation concerns temper the overall score. The earnings call provided a positive outlook, but financial performance remains a critical area for improvement.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences Corporation is a Delaware-based diagnostics company focused on cancer screening and diagnostic testing, operating in the medical technology and life sciences industry and serving healthcare providers and patients through its molecular diagnostic products.
Average Trading Volume: 5,370,568
Technical Sentiment Signal: Buy
Current Market Cap: $19.27B
See more insights into EXAS stock on TipRanks’ Stock Analysis page.